1 0
Cart
    Inquiry
    Popular Searches: Recombinant Antibody MHC Tetramer T cell Receptor Scaffold Protein

    Genetically Modified CHO Cell Prodcuts

    Product List

    + Filter
    Loading...
    View More Products

    Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

    Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

    Introduction: Empowering Biologics with Next-Generation CHO Cell Factories

    As the gold standard for the production of complex therapeutic proteins and monoclonal antibodies, Chinese hamster ovary (CHO) cells are the backbone of the biopharmaceutical industry. However, traditional CHO lines often face bottlenecks such as slow growth, metabolic inefficiency, and suboptimal post-translational modifications.

    Creative Biolabs' CHO cell engineering platform leverages cutting-edge synthetic biology and metabolic engineering to transform wild-type CHO cells into high-performance "cell factories." By targeting specific genetic checkpoints, we enhance secretory capacity, extend culture longevity, and ensure the superior quality of your biological products.

    Fig.1 Genetically Modified in CHO Cells (Creative Biolabs AI)

    Comprehensive CHO Cell Engineering Strategies

    To overcome the inherent biological limitations of wild-type CHO cells, we utilize a variety of genetic manipulation toolsets. These strategies have evolved from simple "gene addition" (overexpression) to precise "gene editing" (CRISPR-mediated knockout) and sophisticated "pathway re-engineering" (combinatorial approaches). By strategically selecting the modification method based on the target gene's biological function-whether it is an essential chaperone, a pro-apoptotic trigger, or a metabolic bottleneck-production titers can be significantly amplified while maintaining superior product quality.

    Strategy Definition & Core Principle Common Technical Methods Impact on Protein/Phenotype
    Overexpression Increasing endogenous gene copy numbers or introducing exogenous genes to significantly boost transcription and translation levels. Plasmid transfection, viral transduction, stable cell line construction (e.g., DHFR/GS systems). "Addition": Enhances specific metabolic pathways or protective mechanisms.
    Knockout (KO) Completely eliminating the function of a target gene so it no longer expresses any biologically active protein. CRISPR/Cas9, ZFNs, TALENs. "Total Deletion": Eliminates harmful metabolites or alters fundamental cell properties.
    Knockdown (KD) Reducing target mRNA levels to decrease protein synthesis without altering the underlying genomic sequence. RNA interference (RNAi), shRNA, siRNA, CRISPRi. "Volume Down": Downregulates expression levels while usually retaining partial function.
    Multiplex Engineering Simultaneously performing multiple types of modifications (e.g., "KO of Gene A + overexpression of Gene B"). Multi-target CRISPR systems, polycistronic co-expression vectors. "Systemic Remodeling": Synergistically optimizes cell factory performance across multiple dimensions.

    Engineering Categories & Functional Solutions

    We categorize our genetic modification services into four core functional modules designed to maximize volumetric productivity and product quality.

    A. Apoptosis & Proliferation Control (Resilience Engineering)

    Strategy: Dual-pathway modification to extend cell longevity.

    Key targets: CRISPR-knockout of pro-apoptotic genes (BAX, BAK1) and overexpression of anti-apoptotic factors (Bcl-xL, MCL1).

    Functional impact: Extends viable culture duration and increases Integral Viable Cell Density (IVCD).

    B. Secretory Pathway & Proteostasis (The "Factory" Expansion)

    Strategy: Enhancing the folding and transport machinery of the ER and Golgi.

    Key targets: Transcription factors (XBP1s, ATF6) and chaperones (P4HB/PDI, HSPA5/BiP).

    Functional impact: Overcomes ER stress, boosts the secretion of "difficult-to-express" proteins, and ensures proper folding.

    C. Metabolic & Epigenetic Rewiring (Efficiency Optimization)

    Strategy: Redirecting carbon flux and maintaining stable transgene expression.

    Key targets: LDHA (Lactate reduction), GLUL/DHFR (Selection systems), and epigenetic markers (DNMTs, TETs).

    Functional impact: Reduces toxic byproduct accumulation and prevents "gene silencing" during long-term passage.

    D. Multi-Target Pathway Engineering (Combinatorial Synergy)

    Strategy: Synergistic modification of multiple nodes across cellular pathways.

    Innovation: Moving beyond single-target OEX (Overexpression) to pathway-guided combinations.

    Functional impact: Achieves up to 10x+ productivity gains compared to single-gene modifications.

    Our Specialized Service Features

    • Precision target selection: We offer a verified database of over 400+ targets, including specific non-coding RNAs (miRNAs/lncRNAs) and uncharacterized loci (LOC series) that significantly impact CHO cell performance.
    • Versatile engineering toolkits: Utilization of stable cell line development (FcRn-overexpressing lines), CRISPR-mediated multi-gene editing, and UCOE/SINEUP technologies for long-term expression stability.
    • High-Throughput screening: Rapid identification of the best-performing clones using automated platforms, ensuring high titer and genetic stability.
    • Custom "Tailor-Made" engineering: Whether you need to reduce host cell proteins (HCPs) or modify a specific metabolic pathway, our team provides end-to-end solutions from design to cell bank characterization.
    • Regulatory-ready documentation: Full traceability of cell line lineage and modification history to support your IND/BLA filings.

    Join the shift toward pathway-oriented multi-target engineering. Contact our technical team today for a customized CHO cell engineering roadmap.

    For Research Use Only. Not For Clinical Use.

    Go to compare

    Go to compare